South-Korean headquartered Samsung Biologics, a global contract development and manufacturing organization (CDMO), today presented its 2024 business plans and strategy at the J.P. Morgan Healthcare Conference held January 8 – 11, 2024 in San Francisco, California.

The J.P. Morgan Healthcare Conference is among of the premier conference and informative health care investment symposium in the industry, connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community.

During the main track presentation, John Rim, Chief Executive Officer and President of Samsung Biologics, announced that the company will continue to add fresh capacity and further diversify its portfolio in the new year to deliver on its commitment to produce high-quality biomedicines and ensure client satisfaction despite a challenging environment.

“This year, we expect to face fiercer competition and challenges as we prepare for the next decade of growth,” said Rim. “We will continue to make bold investments in capacity and geographic expansion to address the growing market demand, while securing core capabilities in new modalities to better serve and meet the evolving needs of our clients.”

Advertisement #3 

Second Bio Campus
Samsung Biologics broke ground on its second Bio Campus last year and has been accelerating the construction of Plant 5, which will bring up the company’s total biomanufacturing capacity to 784,000 liters upon its completion in April 2025. By 2032, Bio Campus II will house four plants, each with a capacity of 180,000 liters, and combined with Bio Campus I, will enable Samsung Biologics to provide over 1.3 million liters’ capacity to clients worldwide.

The company is also building an antibody-drug conjugate (ADC) facility at a separate site, with the aim to commence operations by 2024. The company has been investing in biotech companies with advanced technologies to secure relevant ADC capabilities.

Samsung Biologics also plans to expand its partnerships with both global pharma and emerging biotech companies by offering services incorporating its newly launched CDO platforms, S-CHOsient™ and S-Glyn™, that ensure higher productivity and quality of a molecule for successful drug development.

Geographical expansion
In terms of geographical expansion, Samsung Biologics continues upgrade its capabilities to accommodate clients by investing in technologies such as an antibody-drug conjugate (ADC) development and manufacturing facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. The company is also identifying new sites to work in closer proximity to its clients, in addition to its sales offices in New Jersey and Boston, in the U.S. For example, Samsung Biologics America which held its official opening ceremony on March 19, 2023, enables the company to work in closer proximity to clients based in the U.S. and Europe.

“Our utmost priority will be providing the highest level of customer-centric services by improving all areas of our business through innovation and technology to bring sustainable value to all of our clients and partners,” added Rim.

“We will continue to build on our strong foundation of trust and pursue our mission to deliver high-quality biomedicines to as many patients around the world,” Rim concluded.


Featured image: John Rim, CEO and President of Samsung Biologics. Photo courtesy: © 2024 Samsung Biologics. Used with permission.

Advertisement #4